Short-term reproducibility of gas exchange measurements during bicycle exercise in patients with mild to moderate congestive heart failure

A series of 45 patients with congestive heart failure due to coronary disease had semisupine bicycle exercise tests (ramp protocol, 10 W/min) on two occasions separated by 3 to 7 days in order to determine the short-term reproducibility of gas exchange measurements during symptom-limited exercise. The percentage difference (PD) between each pair of measurements (m1, m2; PD = 100%.(m2-m1): m1) were calculated. The mean PD values (+/- 1 sigma) and the single determination standard deviations (SDSD) for exercise tolerance (ET, W), peak heart rate (pHR, 1/min), peak oxygen uptake (pVO2, ml/min/kg), peak carbon dioxide output (pVCO2, ml/min/kg), and peak minute ventilation (pVE, l/min) were as follows: [table: see text] No patient reached a plateau of oxygen uptake during the last portion of the ramp exercise test. Thus, pVO2 is not an objective endpoint. The single determination standard deviations show that exercise tolerance and peak oxygen uptake do not differ as to their reproducibility. The absolute values of PD were not a function of exercise tolerance for any of the parameters studied. The PD values for ET and pVO2 were normally distributed. The data suggest that a change in ET and pVO2 must exceed 27% and 28% between two sequential studies in an individual patient in order to be significant at the 5% level, respectively. For the one-tailed test situation, the changes in ET or pVO2 must be greater than 23% in order to be significant.

Effects of atenolol, slow-release nifedipine, and their combination on respiratory gas exchange and exercise tolerance in stable effort angina

The effects of atenolol, nifedipine, and their combination on gas exchange and exercise tolerance were studied in 27 patients with effort angina and normal global ventricular function in an open-label and randomized cross-over trial. Symptom-limited semi-supine exercise tests using a ramp protocol (20 W/min) with simultaneous breath-by-breath analysis of gas exchange were carried out after a 4-day wash-out period and after consecutive 2-week treatment periods with atenolol (50 mg b.i.d.), slow-release nifedipine (20 mg b.i.d.), and their combination (b.i.d.). Exercise tolerance was not significantly higher with atenolol than with nifedipine [118(24) vs 113(23) W]. Combination therapy [120(23) W] was more effective than monotherapy with nifedipine (p less than 0.05) but produced no further increase in exercise tolerance over atenolol monotherapy. Maximum oxygen uptake was not significantly different among the treatments. In the range of light to moderate exercise, the slope of the VO2-workload regression line expressed as ml.min-1.W-1 was lower with atenolol than with nifedipine [8.64(1.59) vs 10.28(1.74), p less than 0.005] and intermediate with combination therapy [9.99(1.83)]. The intercept on the VO2 axis was higher with atenolol than with nifedipine [366(111) vs 299(113) ml.min-1, p less than 0.05]. A similar pattern of results was seen when the drug effects on the slope of the VCO2-workload relation were analyzed. VE was higher with nifedipine than with atenolol at all points of the regression analysis [greater than 30 W].(ABSTRACT TRUNCATED AT 250 WORDS)

Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure--a placebo-controlled trial

To evaluate the acute and chronic effects of diuretic monotherapy with 3 mg piretanide bid, 46 patients (pts) with congestive heart failure (NYHA II-III) secondary to coronary artery disease were studied. Within 3 weeks of therapy, the patients lost 1.6 kg body weight. Forty-four patients reported a subjective feeling of improvement. Echocardiographically, a highly significant (p less than 0.001) reduction of diastolic and systolic diameters was found, as well as an increase of fraction shortening. Chest x-ray indicated a reduction of heart volume from 1012 +/- 263 ml to 936 +/- 233 ml (p less than 0.001). The serum potassium level remained unchanged. A subgroup of 26 pts underwent invasive hemodynamic examinations. IV injection of 6 mg piretanide resulted in an acute reduction of pulmonary wedge pressure (pc) from 20.2 +/- 5.3 mmHg to 11.9 +/- 5.0 mmHg (p less than 0.001); simultaneously a slight decrease of cardiac index from 3.2 +/- 0.6 l/min/m2 to 3.0 +/- 0.4 l/min/m2 was observed. Invasive control after 3 weeks of oral therapy showed no decline of the piretanide effect. The exercise tolerance increased clearly from 135 +/- 161 Wmin to 249 +/- 268 Wmin (p less than 0.05). A control group of further 14 pts was treated with placebo only and did not show any significant changes of pc (20.0 +/- 6.4 mmHg vs. 22.8 +/- 19.2 mmHg), exercise tolerance, or other clinical parameters. Thus, the diuretic monotherapy of congestive heart failure with piretanide is highly effective and shows a significant improvement in all clinical and hemodynamic parameters in the absence of any remarkable side effects.

Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype

The risk of lung cancer in smokers was examined based on the debrisoquine metabolic phenotype and on exposure to occupational lung carcinogens, specifically asbestos and polycyclic aromatic hydrocarbons. Extensive metabolizers of debrisoquine are at a 4-fold increased risk for lung cancer compared to poor metabolizers, after adjustment for age, sex, and smoking (pack-years), when only occupationally unexposed subjects are considered. Increased risk related to the debrisoquine metabolic phenotype was greatest for squamous and small cell histologies, and least for the adenocarcinoma subtype. Men with a history of exposure to occupational carcinogens had significantly increased risk of lung cancer (relative risk = 2.8), after adjustment for age and smoking. Considering the combined effect of the high risk extensive metabolizers debrisoquine metabolic phenotype and likely occupational exposure to asbestos, the relative excess risk for lung cancer was 18-fold. This finding is consistent with a synergism in risk between the ability to extensively metabolize debrisoquine and occupational exposure to lung carcinogens in male smokers. Debrisoquine phenotyping has potential for identifying carcinogen-exposed workers at high risk of lung cancer.

The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk

Debrisoquine hydroxylation exhibits wide inter-individual variation in Caucasian populations. After similar doses of the drug, extensive metabolizers excrete up to several hundred times more of the urinary metabolite 4-hydroxy-debrisoquine than do poor metabolizers. The phenotypes have traditionally been defined by the metabolic ratio (MR), or the molar ratio of debrisoquine to its chief metabolite recovered in an aliquot of an eight hour urine sample, after a test dose of the drug. Deficient metabolism is inherited as an autosomal recessive condition. We have reanalyzed previously published data from a study of lung cancer patients and controls using a computerized optimization method to more accurately estimate the parameters describing the three phenotypic distributions. Using these new distributions to categorize controls, we show that Hardy-Weinberg conditions are now fulfilled. When the newly defined phenotype parameters are employed to assign the phenotypes of cases and controls, a highly significant difference in phenotype distribution between cases and controls is still observed. This result supports the hypothesis that the debrisoquine metabolic phenotype may be associated with lung cancer susceptibility.